SCHEMBL4829133

SCHEMBL4829133

Nc1ccc(Cc2nc3ccccc3o2)cc1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.83
TP53 P04637 3/20 0.83
LMNA P02545 1/20 0.83
NPC1 O15118 6/20 0.74
RAB9A P51151 5/20 0.74
MAPT P10636 4/20 0.74
HTT P42858 1/20 0.74
GFER P55789 1/20 0.74
USP2 O75604 1/20 0.64
MAPK10 P53779 1/20 0.64
POLB P06746 2/20 0.60
LOXL2 Q9Y4K0 1/20 0.60
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
ATM Q13315 1/20 0.54
GRK6 P43250 1/20 0.53
KDM4E B2RXH2 2/20 0.50
HSD17B10 Q99714 2/20 0.50
CYP3A4 P08684 2/20 0.50
CYP1A2 P05177 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13053140 0.86 SMN1; SMN2 (0.89) SMN1; SMN2TP53LMNANPC1RAB9A
SCHEMBL4650036 0.86 TP53 (0.89) SMN1; SMN2TP53LMNANPC1RAB9A
SCHEMBL31265474 0.83 SMN1; SMN2 (0.83) SMN1; SMN2TP53LMNANPC1RAB9A
SCHEMBL1906381 0.83 SMN1; SMN2 (0.83) SMN1; SMN2TP53LMNANPC1RAB9A
SCHEMBL10849069 0.83 TP53 (0.83) SMN1; SMN2TP53LMNANPC1RAB9A
SCHEMBL31265500 0.83 SMN1; SMN2 (0.83) SMN1; SMN2TP53LMNANPC1RAB9A
SCHEMBL4688937 0.83 SMN1; SMN2 (0.83) SMN1; SMN2TP53LMNANPC1RAB9A
SCHEMBL1906504 0.83 TP53 (0.83) SMN1; SMN2TP53LMNANPC1RAB9A
SCHEMBL3821992 0.83 SMN1; SMN2 (0.83) SMN1; SMN2TP53LMNANPC1RAB9A
SCHEMBL1420033 0.82 TP53 (0.81) SMN1; SMN2TP53LMNANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287438-A1 Agent for preventing or treating neuropathy MOMOSE YU 2008-11-20 US disclosed
US-7423159-B2 Agent for preventing or treating neuropathy TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-09-09 US disclosed
US-20060004069-A1 Agent for preventing or treating neuropathy TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-01-05 US disclosed
CN-1026322-C Process for preparing benzodumb azole derivatives TANABE SEIYAKU CO (JP) 1994-10-26 CN disclosed
CN-88101542-A Benzoxazole derivatives and process for preparing them 1988-10-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004069-A1 Agent for preventing or treating neuropathy NR2C2, NR0B2, NR2E1 SMN1; SMN2 75/4885TP53 4623/4885LMNA 2405/4885
US-20080287438-A1 Agent for preventing or treating neuropathy NR2C2, NR0B2, NR2E1 SMN1; SMN2 75/4885TP53 4623/4885LMNA 2405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.